Partial Draft of Neandertal Genome
The first chunk of the Neandertal genome was published today in the journal Nature. It reveals that modern humans and our ancient cousins diverged about 500,000 years ago. The sequence, derived from a 38,000-year-old bone fragment found in a cave in Croatia, was made possible by a new sequencing technology developed by 454 Life Sciences . According to Michael Egholm, one of the 454 Life Sciences project’s leaders, who talked to Technology Review in September, the Neandertal genome will shed light on the genetic changes that make us uniquely human. “We believe we can use the Neandertal genome as a signpost for our own genome,” he says. “Our approach is to look at the 35 million base pair differences between chimp and man. Then we ask a simple question: Is Neandertal like chimp or human on those sites?” (Click here for the full text of the Q&A.)
From the paper:
Neanderthals are the extinct hominid group most closely related to contemporary humans, so their genome offers a unique opportunity to identify genetic changes specific to anatomically fully modern humans. We have identified a 38,000-year-old Neanderthal fossil that is exceptionally free of contamination from modern human DNA. Direct high-throughput sequencing of a DNA extract from this fossil has thus far yielded over one million base pairs of hominoid nuclear DNA sequences. Comparison with the human and chimpanzee genomes reveals that modern human and Neanderthal DNA sequences diverged on average about 500,000 years ago. Existing technology and fossil resources are now sufficient to initiate a Neanderthal genome-sequencing effort.
Keep Reading
Most Popular
The inside story of how ChatGPT was built from the people who made it
Exclusive conversations that take us behind the scenes of a cultural phenomenon.
How Rust went from a side project to the world’s most-loved programming language
For decades, coders wrote critical systems in C and C++. Now they turn to Rust.
Design thinking was supposed to fix the world. Where did it go wrong?
An approach that promised to democratize design may have done the opposite.
Sam Altman invested $180 million into a company trying to delay death
Can anti-aging breakthroughs add 10 healthy years to the human life span? The CEO of OpenAI is paying to find out.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.